AU5590596A - Use of calpain inhibitors in the inhibition and treatment of neurodegeneration - Google Patents

Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Info

Publication number
AU5590596A
AU5590596A AU55905/96A AU5590596A AU5590596A AU 5590596 A AU5590596 A AU 5590596A AU 55905/96 A AU55905/96 A AU 55905/96A AU 5590596 A AU5590596 A AU 5590596A AU 5590596 A AU5590596 A AU 5590596A
Authority
AU
Australia
Prior art keywords
neurodegeneration
inhibition
treatment
calpain inhibitors
calpain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55905/96A
Inventor
Raymond T Bartus
David D. Eveleth Jr.
Garry S Lynch
James C Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Cortex Pharmaceuticals Inc
Original Assignee
Georgia Tech Research Institute
Georgia Tech Research Corp
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Institute, Georgia Tech Research Corp, Cortex Pharmaceuticals Inc filed Critical Georgia Tech Research Institute
Publication of AU5590596A publication Critical patent/AU5590596A/en
Priority to AU23782/99A priority Critical patent/AU2378299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU55905/96A 1990-12-28 1996-06-11 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration Abandoned AU5590596A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23782/99A AU2378299A (en) 1990-12-28 1999-04-15 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63595290A 1990-12-28 1990-12-28
US635952 1990-12-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU91527/91A Division AU667463B2 (en) 1990-12-28 1991-12-27 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU23782/99A Division AU2378299A (en) 1990-12-28 1999-04-15 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
AU5590596A true AU5590596A (en) 1996-08-22

Family

ID=24549781

Family Applications (2)

Application Number Title Priority Date Filing Date
AU91527/91A Ceased AU667463B2 (en) 1990-12-28 1991-12-27 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
AU55905/96A Abandoned AU5590596A (en) 1990-12-28 1996-06-11 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU91527/91A Ceased AU667463B2 (en) 1990-12-28 1991-12-27 Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Country Status (5)

Country Link
EP (1) EP0564552A1 (en)
JP (1) JPH06504061A (en)
AU (2) AU667463B2 (en)
CA (1) CA2098609A1 (en)
WO (1) WO1992011850A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
US5637589A (en) * 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5536639A (en) * 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US6319929B1 (en) 1994-04-29 2001-11-20 The University Of North Carolina At Chapel Hill Suksdorfin analogs, compositions thereof, and methods for making and using thereof
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU3935895A (en) * 1994-11-24 1996-06-17 Takeda Chemical Industries Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5827877A (en) * 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
ES2293651T3 (en) * 1995-11-28 2008-03-16 Cephalon, Inc. INHIBITORS OF CYSTEINE AND SERINE PROTEASES DERIVED FROM AMINO ACIDS D.
DE19642591A1 (en) * 1996-10-15 1998-04-16 Basf Ag New piperidine-ketocarboxylic acid derivatives, their production and use
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
DE19650975A1 (en) 1996-12-09 1998-06-10 Basf Ag New heterocyclically substituted benzamides and their application
WO1998025883A1 (en) * 1996-12-11 1998-06-18 Basf Aktiengesellschaft Ketobenzamides as calpain inhibitors
ID27507A (en) * 1998-03-20 2001-04-12 Senju Pharma Co PHARMACEUTICAL COMPOSITION THAT CONTAINS INHIBITORS OF CYCLEIN PROTEASE FOR PREVENTION AND TREATMENT OF BRAIN NETWORK
DE19817459A1 (en) 1998-04-20 1999-10-21 Basf Ag New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
EP1073641B1 (en) 1998-04-20 2004-04-14 Abbott GmbH & Co. KG New substituted amides, their production and their use
DE19818614A1 (en) 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
DE59914996D1 (en) 1998-04-20 2009-05-14 Abbott Gmbh & Co Kg Heterocyclisch substituierte amide als calpainhemmer
ATE344794T1 (en) * 1998-05-25 2006-11-15 Abbott Gmbh & Co Kg HETEROCYCLIC SUBSTITUTED AMIDES, THEIR PREPARATION AND USE
AU1708099A (en) 1998-06-03 1999-12-20 Amgen, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
BR0112666A (en) 2000-07-21 2003-06-10 Schering Corp Peptides as inhibitors of hepatitis C virus ns3-serine protease
DK1385870T3 (en) 2000-07-21 2010-07-05 Schering Corp Peptides as inhibitors of NS3 serine protease from hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
FR2817867B1 (en) * 2000-12-11 2006-06-30 Trophos ISOCOUMARINS INHIBITORS OF AMYLOID PEPTIDE PRODUCTION, PREPARATION, COMPOSITIONS CONTAINING SAME AND USES THEREOF
DE10105041A1 (en) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
DE10105038B4 (en) 2001-02-05 2005-07-07 Neurotell Ag Tripeptide derivatives for the treatment of postläsional diseases of the nervous system
DE10105040A1 (en) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide derivatives for the treatment of post-lesion diseases of the nervous system
EP1465862A1 (en) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
EP3220935A4 (en) * 2014-11-11 2018-12-26 Western University Of Health Sciences Isoform-specific calpain inhibitors, methods of identification, and uses thereof

Also Published As

Publication number Publication date
AU9152791A (en) 1992-08-17
WO1992011850A3 (en) 1992-09-03
JPH06504061A (en) 1994-05-12
WO1992011850A2 (en) 1992-07-23
EP0564552A1 (en) 1993-10-13
AU667463B2 (en) 1996-03-28
CA2098609A1 (en) 1992-06-29

Similar Documents

Publication Publication Date Title
AU5590596A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
EP0520336A3 (en) Aldehyde derivatives and their use as calpain inhibitors
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
HU9403655D0 (en) Methods of inhibiting atrophy of the skin and vagina
SG93751A1 (en) Bioadhesive treatment compositions and methods of use
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU5590696A (en) Use of quinones in the treatment of cancer or AIDS
AU6946594A (en) Methods for the treatment and prevention of diarrhea
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU1556497A (en) Agents for the treatment and prevention of aids
AU8427091A (en) Gamma-carboxylase and methods of use
PL311300A1 (en) 4-arylo-4-hydroxy-tetrahydropyranes and 3-arylo-3-hydroxy-tetrahydrofuranes as inhibitors of 5-lipoxygenase
GB2271579B (en) Treatment of wood
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU4812393A (en) Use of rapamycin in the treatment of aids
EP0688225A4 (en) Methods and compositions for the inhibition of complement activation
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU4319393A (en) Use of indolocarbazols in aids treatment
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
AU3456793A (en) Macrocyclic compounds in the prophylactic treatment of aids
IL128095A0 (en) Formulation for the treatment and/or prophylaxis of dementia
GB9317943D0 (en) Treatment of laminitis